CARB-X

CARB-X is excited to welcome its newest funder! The Government of #Italy announced a commitment of US$21 million over the next three years to CARB-X at the G7 Joint Finance Health and Ministers’ Meeting last week. New funding from Italy will enhance CARB-X’s efforts to support, accelerate, and coordinate the early-stage development of innovative products aimed at preventing, diagnosing, and treating drug-resistant bacterial infections, a leading cause of death around the world, particularly in low- and middle-income countries (LMICs). “We are profoundly grateful to the Italian Government for their generous support,” said Kevin Outterson, Executive Director of CARB-X and Austin B. Fletcher Professor of Law at Boston University. “Italy’s investment is a powerful addition to the support we receive from a global consortium of funders, including other G7 governments and leading global health foundations. This collective effort underscores the critical importance of international collaboration in the fight against antimicrobial resistance. Together, we are driving innovation and ensuring that the most promising research can be translated into life-saving treatments for patients worldwide.”? ? ?? Read our press release here: bit.ly/3UckAiJ ? #AMR #StopSuperBugs #AntimicrobialResistance #G7 #Medicine #GlobalHealth

??? New interview!? ? CARB-X Chief of Research and Development Erin Duffy, PhD spoke with WuXi AppTec about CARB-X's pivotal work to advance innovative antibacterial products through the development pipeline. She discussed some of the projects CARB-X is supporting and the challenges that are encountered in early drug development in the antimicrobial resistance (AMR) industry. CARB-X launched several Portfolio Acceleration Tools to address these challenges, benefit the larger AMR ecosystem, and accelerate drug development. “We’ve observed common hurdles. One approach could be to address these individually, but we’ve found it more effective to take a proactive approach,” said Dr. Duffy. “Our goal is simple: if we can clear a path for one, we aim to clear it for all.” ?? Read here: bit.ly/3CACbea #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

CARB-X graduate Pattern Bioscience receives support from Biomedical Advanced Research and Development Authority (BARDA) to further develop its rapid #diagnostic to determine the effectiveness of antibiotics against specific bacteria. Rapid diagnostics are vital for improving the treatment of drug-resistant infections, as current laboratory testing can take days to reach a diagnosis. Faster test results would enable medical staff to treat infections quickly with the appropriate antibiotic.? ? #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

?? New podcast! CARB-X Chief of External Affairs Damiano de Felice joined the Canadian Antimicrobial Innovation Coalition (CAIC)’s podcast, the AMR Action Podcast, to discuss the Government of #Italy's recent commitment to CARB-X and considerations other governments should prioritize to address antimicrobial resistance (AMR). He spoke about the intersection of innovation and access, emphasizing the importance of collaboration among world leaders and governments to find global solutions to address AMR. ?? Listen here: bit.ly/3ZdXDyg #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

??? New interview!? ? Kevin Outterson, CARB-X Executive Director and Austin B. Fletcher Professor of Law at Boston University, spoke with Global Health Now, Johns Hopkins Bloomberg School of Public Health’s publication, about how a better business model is needed to prevent the collapse of the antibiotic development pipeline. Investments into push and pull incentives have increased in recent years, but still lag behind necessary levels to bring enough new antibiotics to the market. Prof. Outterson emphasized that antibiotics should be valued based on their benefit to society rather than their volume of sales. ?? Read here: bit.ly/3CFcCsr #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology

Antimicrobial-resistant (AMR) bacteria and fungi are serious health security threats to people in the United States and throughout the world. We provide financial support and technical expertise to develop medical countermeasures that address drug-resistant secondary infections with the goal of regulatory approval and potential procurement. This approach helps bolster national security and protects people from the health consequences that could occur following a chemical, biological, radiological, or nuclear (CBRN) incident. This U.S. Antibiotic Awareness Week (#USAAW), learn more about our efforts to combat AMR and the partnerships that make it happen: https://ow.ly/k1Eq50U8f6c To learn more about our recent AMR work, including ways to partner with us, visit: https://ow.ly/wZia50U8f6b

Exciting News! ?? We're proud to announce the extension of funding from CARB-X supporting the preclinical development of Debio 1453, our anti-gonorrhoea program. We perceive these newly awarded $5.76 million USD as a recognition of our efforts combating the threat of antimicrobial resistance. ?? Read more in our latest press release: https://lnkd.in/eXDPs75t #antimicrobialresistance #globalhealth #drugresistance #antibiotics

#BULawProf and CARB-X executive director Kevin Outterson explains that the fight against antimicrobial resistance needs a better business model, proposing that antibiotic researchers and their output need to be valued, “not based on the volume of sales, but on their value to society.” ?? https://spr.ly/6044svyeq

On CAIC's #AMR Action Podcast, Damiano de Felice, CARB-X, shares his experience working with the Italian government to help implement push and pull incentives to accelerate research and development of new #antimicrobials. Tune in to the full episode on Apple Podcasts or Spotify! https://lnkd.in/gCfEF7yX #WAAW2024 #G7 #AntimicrobialResistance

??? Day 2: The Power of Public-Private Partnerships in Controlling AMR ??? Today, we shine a spotlight on the collaboration between industry and the public sector in our efforts to mitigate AMR. Public-private partnerships are essential for driving innovation, advancing research, and implementing effective solutions to curb AMR. ???? "Developing innovative antibacterial products and making them accessible worldwide are complex objectives that require all hands on deck. From our experience at CARB-X, it is crystal-clear that leveraging the combined resources and expertise of governments, industry, academia and civil society is the only way to stay ahead in the fight against drug-resistant bacteria. This is why public-private partnerships are so crucial if we want to stop superbugs." Damiano de Felice, Chief of External Affairs, CARB-X These partnerships are paving the way for new antimicrobial products, better diagnostic tools, and innovative strategies. By combining the strengths of private companies and public organisations, we can leverage resources and expertise to create sustainable solutions. We encourage industry stakeholders to actively engage in the fight against AMR by: ?? Investing in R&D - Support the development of new antimicrobial agents and alternatives. ?? Collaborating - Partner with public entities and other organisations to share knowledge and resources. Let’s harness the power of public-private partnerships to create a healthier future for all! ???? Stay tuned for more insights as we continue our journey through #WAAW2024! #OneHealth #EducateAdvocateAct #GlobalCollaboration #AMR Video credit: WHO